Alkem, INE540L01014

Alkem Stock - weekly review in a muted pharma sector

Published on 06/19/2026 at 19:39 | Editorial responsibility: Rafael MĂĽller, Editor-in-Chief AD HOC NEWS

Alkem Laboratories closes a mostly steady week on Mumbai’s exchanges, with pharma peers showing only limited momentum. A look at the recent share performance, sector moves and what is next on the earnings calendar.

Alkem, INE540L01014, Illustration mit AI erstellt.
Alkem, INE540L01014, Illustration mit AI erstellt.

Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 17:30 UTC. Details in the imprint.

Alkem (INE540L01014) is heading into the weekend after a largely stable trading week on the Indian market. The stock’s moves remained modest as investors took their cues from a broadly cautious pharmaceuticals sector.

Go deeper

Background and recent data on Alkem stock

Key figures, disclosures and further reporting on Alkem Laboratories can be found in dedicated stock and investor-relations overviews.

How Alkem shares fared this week

Alkem shares traded in a relatively narrow band this week, with recent prices around INR 5,350 on the National Stock Exchange according to indicative quote data from Moneycontrol. Intraday ranges stayed moderate, signaling limited short-term repositioning.

Over the past month, the stock has moved between roughly INR 4,700 and INR 5,900, based on chart data from Indian quote services. That puts Alkem moderately below its recent peak, but well above the lower end of its 52-week range.

Sector moves and peer comparison

Indian pharmaceutical names overall have shown a mixed performance in recent sessions, with selective strength in companies exposed to US generics and chronic therapies. Benchmark pharma indices on Mumbai’s exchanges have largely traded sideways this week, according to local market overviews.

Against this backdrop, Alkem’s muted week looks broadly consistent with its peer group. Short-term news flow was limited, so investors appeared to focus more on medium-term demand trends and regulatory developments in key export markets.

How the company makes money

Alkem Laboratories Ltd generates most of its revenue from branded generics and generics, including anti-infective, gastro-intestinal and pain-management therapies, alongside a US generics franchise, as outlined in its latest annual report and corporate profile.

Where the stock trades today

The shares of Alkem (INE540L01014) last traded on the National Stock Exchange of India at around INR 5,350 as of 06/19/2026, 17:15 IST.

Key facts on Alkem stock

  • Company: Alkem Laboratories Ltd
  • ISIN: INE540L01014
  • WKN: A14UFW
  • Ticker: ALKEM
  • Venue: NSE (India)
  • Price (as of 06/19/2026, 17:15 IST): 5,350.00 INR
  • Market cap: 639,000,000,000 INR (as of 06/19/2026)
  • Sector / Industry: Health Care / Pharmaceuticals
  • Index membership: Nifty 200
  • Next earnings date: 07/26/2026

More on Alkem stock on social media

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.

Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.

en | INE540L01014 | ALKEM | boerse | 69584660 | bgmi